Want to see SE:NXTCL full AI Analyst Report?
NextCell Pharma AB (NXTCL) Financial Statements
NextCell Pharma AB Financial Overview
NextCell Pharma AB's market cap is currently $29.07M. The company's EPS TTM is $-0.38; its P/E ratio is -0.60; NextCell Pharma AB is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Aug 25 | Aug 24 | Aug 23 | Aug 22 | Aug 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 10.94M | $ 10.66M | $ 10.11M | $ 5.59M | $ 3.91M |
| Gross Profit | $ -35.87M | $ -4.56M | $ -884.83K | $ -22.26M | $ -14.53M |
| Operating Income | $ -35.87M | $ -43.17M | $ -41.00M | $ -35.02M | $ -24.82M |
| EBITDA | $ -32.63M | $ -40.99M | $ -39.36M | $ -34.10M | $ -24.21M |
| Net Income | $ -35.14M | $ -41.96M | $ -39.81M | $ -34.08M | $ -24.56M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 38.72M | $ 46.79M | $ 50.03M | $ 97.12M | $ 139.17M |
| Total Assets | $ 76.73M | $ 81.29M | $ 88.83M | $ 124.66M | $ 155.63M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -38.72M | $ -46.79M | $ -50.03M | $ -97.12M | $ -139.17M |
| Total Liabilities | $ 10.34M | $ 13.69M | $ 13.10M | $ 9.12M | $ 5.53M |
| Stockholders' Equity | $ 66.39M | $ 67.60M | $ 75.73M | $ 115.54M | $ 150.09M |
| Cash Flow | |||||
| Free Cash Flow | $ -43.05M | $ -37.86M | $ -47.92M | $ -40.90M | $ -26.30M |
| Operating Cash Flow | $ -38.86M | $ -37.78M | $ -43.83M | $ -33.31M | $ -25.58M |
| Investing Cash Flow | $ -4.24M | $ -83.51K | $ -4.10M | $ -9.37M | $ -5.84M |
| Financing Cash Flow | $ 35.03M | $ 34.63M | $ 835.66K | $ 608.17K | $ 148.63M |
Currency in SEK